May 18, 2018 09:45 AM EDTUpdated 10:07 AM
R&D

Ag­ile bris­tles af­ter FDA's third snub, promis­ing a fight for its con­tra­cep­tive

Brittany Meiling

Ag­ile Ther­a­peu­tics is start­ing to get testy af­ter suf­fer­ing yet an­oth­er snub from the FDA, an­nounc­ing this morn­ing that it sim­ply doesn’t agree with the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

FDA ap­proves PTC’s ul­tra-rare dis­ease gene ther­a­py for broad­er pa­tient pop­u­la­tion than Eu­rope

Met­sera rais­es $215M for stud­ies of GLP-1 and amylin obe­si­ty drugs

GSK makes case for Blenrep's re­turn with new blood can­cer sur­vival da­ta

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times